gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · EYPTHealthcareLab Analytical Instruments

EyePoint, Inc. Common Stock (EYPT)

$0.3950−1.23%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.40▼ 96.81% in range
Nov 4, 2025Low $0.35 · High $18.85Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

EyePoint closed at $0.40 on Nov 4, down 1.23%, 97.9% below its 52-week closing high. Volume of 3.1M shares was 0.17× its 20-day average (below normal).

Split-adjusted performance: -87.5% over one month, -97.0% over six months, -96.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $507K, down 90.5% from a year earlier, with a net margin of -18633.1%.

Short interest was 21.3M shares at the Oct 15 settlement, up 2.3% from the prior report (25.5% of float, 8.1 days to cover).

Market cap$34.1M86.2M shares
Revenue · quarter$507.0K−90.5% YoY
Diluted EPS$-1.09—
P/E · TTM—P/S 12.2×
Net margin-18,633.1%Gross 100.0%
Dividend yieldNone
52-week range0.35 – 18.85−97.9% from high
Volume3.1M0.17× 20-day avg
Volatility · 60d454.3%Annualised
Short % of float25.5%8.1 days to cover
Net cash$180.5MCash $180.5M
Next earnings—Not scheduled
Split-adjusted performance
1W +4.7%1M −87.5%3M −96.9%6M −97.0%YTD −97.8%1Y −96.8%3Y −93.1%5Y −96.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Lab Analytical Instruments

Percentile among 22 companies (100 = best)

6-month momentum0
Revenue growth0
Net margin0
Value (low P/E)—
Size10

Industry medians: 6-month return +33.8%, revenue growth +4.9%, net margin −19.0%, P/E 38.3×.

Short interest

Details →
Shares short21.3M+2.3% vs prior
Days to cover8.1Settled Oct 15
% of float25.5%
Short vol. 10d59.9%of daily volume

Closest peers by size in Lab Analytical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
EYPTEyePoint$0.3950−1.23%−97.0%−90.5%−18633.1%—$34.1M
RPIDRapid Micro Biosystems$0.6814−1.53%−73.1%+10.9%−160.5%—$34.2MCompare
PRPOPrecipio$19.57+5.10%−34.7%+24.7%−3.1%—$35.0MCompare
HBIOHarvard Bioscience$8.61−0.69%+18.9%+11.1%−12.8%—$39.2MCompare
BNGOBionano Genomics$1.19−0.83%−6.3%+21.4%−90.8%—$16.6MCompare
SEERSeer$1.70−1.73%−10.1%−23.4%−544.8%—$94.1MCompare
ASTCAstrotech Corporation (DE)$4.51−7.20%+62.2%−42.7%−2592.1%—$9.5MCompare
QTRXQuanterix$3.04+3.40%−7.6%+34.4%−148.7%—$143.8MCompare
NAUTNautilus Biotechnolgy$2.29−2.55%−22.1%—−6682.1%—$291.7MCompare

News about EyePoint

All news →
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research · Oct 28, 2026NeutralINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTGlobeNewswire Inc. · Oct 27, 2026▼ NegativeEyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMDGlobeNewswire Inc. · Oct 19, 2026▼ NegativeHere's Why You Should Add EYPT Stock to Your Portfolio NowZacks Investment Research · Oct 15, 2026NeutralEyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law FirmGlobeNewswire Inc. · Sep 4, 2026▼ Negative

Quick answers

What does EyePoint do?
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden.
What is EYPT's market cap?
$34.05M, based on the Nov 4 close of $0.40.
Does EyePoint pay a dividend?
No regular cash dividend has been paid in the last year.
How much of EYPT is sold short?
21.3M shares, 25.5% of float, as of Oct 15, 2026.
What sector is EYPT in?
Healthcare, in the Lab Analytical Instruments industry.

About EyePoint

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

HQ: Watertown, MA214 employeesListed Jan 27, 2005eyepoint.bio

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology